It’s fair to say shareholders of Adelaide-based pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX) are having a great day. Its share price surged 9.5% higher this morning to $1.73 following the launch of yet another product in the United States.
Hot on the heels of yesterday’s joint announcement with IDT Australia Limited (ASX: IDT), which revealed that IDT’s generic temozolomide brain cancer drug is ready for launch into a US market worth an estimated $205 million per year, Mayne Pharma announced today that it has launched its morphine sulfate extended-release (MSER) tablets in the United States.
The drug is a generic version of MS Contin which is an opioid analgesic used for moderate to severe pain management. According to the release U.S. brand and generic sales of MSER tablets were approximately US$280 million for the 12 months ending 31 August 2016.
This is just one of a number of generic drugs that the company will launch in the foreseeable future. Thanks largely to the portfolio of drugs the company acquired from pharmaceutical giants Teva Pharmaceutical and Allergan this year, Mayne Pharma currently has a pipeline of more than 40 generic and branded drug products.
Management estimates that this pipeline has annual sales potential in the US market of greater than US$7 billion at present.
So with Mayne Pharma’s share price down 15% in the last 30 days, I’m not at all surprised to see its shares rally on this news. As I said a few days ago, now could be an opportune time to make an investment in this exciting company.
It has enormous long-term growth potential in my eyes, and at under 18x estimated FY 2017’s earnings I think it is a great and cheaper alternative to industry heavyweight CSL Limited (ASX: CSL).
I would suggest making room in your portfolio for Mayne Pharma by selling these rotten ASX shares if you own them. Each could be harming your portfolio and might be best kicked out if you ask me.
After a double-digit rally for the ASX since 2016 lows, investors should be on high alert. You’ll find a full rundown below of 3 shares we think you should avoid today plus one top pick worth buying, even if the market turns south and the RBA keeps rates at an “emergency low.” Simply click here to uncover these stocks.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.